Display options
Share it on

J Neurogastroenterol Motil. 2018 Jul 30;24(3):490-501. doi: 10.5056/jnm17035.

The Protective Effect of .

Journal of neurogastroenterology and motility

Fatemeh Dolatabadi, Amir H Abdolghaffari, Mohammad H Farzaei, Maryam Baeeri, Fatemeh S Ziarani, Majid Eslami, Mohammad Abdollahi, Roja Rahimi

Affiliations

  1. Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  2. Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran.
  3. Department of Pharmacology and Toxicology and Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  4. Gastrointestinal Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
  5. Pharmaceutical Sciences Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  6. Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  7. Department of Anatomy, School of Medicine, Ghazvin University of Medical Sciences, Ghazvin, Iran.
  8. Department of Traditional Pharmacy, School of Traditional Medicine, Tehran University of Medical Sciences, Tehran, Iran.

PMID: 29879761 PMCID: PMC6034661 DOI: 10.5056/jnm17035

Abstract

BACKGROUND/AIMS: The aim of present study is to estimate the effects of

METHODS: Two individual models of IBS were induced in male Wistar-albino rats. In the acetic acid model, the animals were exposed to rectal distension and abdominal withdrawal reflex, and the defecation patterns were determined. In the restraint stress model, the levels of TNF-α, myeloperoxidase, lipid peroxidation, and antioxidant powers were determined in the (removed) colon. Rats had been treated with MO, L-NG-nitroarginine methyl ester (L-NAME), aminoguanidine (AG), MO + AG, or MO + L-NAME in the mentioned experimental models.

RESULTS: Hypersensitive response to rectal distension and more stool defecation in control rats have been observed in comparison to shams. MO-300 significantly reduced VH and defecation frequency in comparison to controls. VH and defecation pattern did not show significant change in AG + MO and L-NAME + MO groups compared to controls. Also, significant reduction in TNF-α, myeloperoxidase, thiobarbituric acid reactive substances (TBARS), and an increase in antioxidant power in MO-300 group was recorded compared to controls. AG + MO and L-NAME + MO groups showed a reverse pattern compared to MO-300 group.

CONCLUSIONS: MO can ameliorate IBS by modulating VH and defecation patterns. Antioxidant and anti-inflammatory properties along with its effect on the nitrergic pathway seem to play important roles in its pharmacological activity.

Keywords: Irritable bowel syndrome; Lemon balm; Melissa officinalis; Nitric oxide; Visceral hypersensitivity

References

  1. J Gastroenterol. 2007 Jan;42 Suppl 17:48-51 - PubMed
  2. J Gastroenterol. 2011 Feb;46(2):164-74 - PubMed
  3. Expert Rev Gastroenterol Hepatol. 2015 Jun;9(6):807-20 - PubMed
  4. Fitoterapia. 2003 Jul;74(5):445-52 - PubMed
  5. Med Sci Monit. 2013 Sep 13;19:762-6 - PubMed
  6. Dig Dis Sci. 2012 Feb;57(2):311-9 - PubMed
  7. Mol Cell Biochem. 2012 Mar;362(1-2):43-53 - PubMed
  8. Nat Prod Commun. 2014 Jan;9(1):121-4 - PubMed
  9. Pharm Biol. 2015 Mar;53(3):429-36 - PubMed
  10. Pharmacol Biochem Behav. 2009 Jul;93(1):10-6 - PubMed
  11. Gastroenterology. 2007 May;132(5):1791-803 - PubMed
  12. J Neurogastroenterol Motil. 2017 Jan 30;23(1):20-26 - PubMed
  13. Eur Neuropsychopharmacol. 2011 Dec;21(12):841-60 - PubMed
  14. Eur J Pharmacol. 2015 Jan 5;746:282-92 - PubMed
  15. World J Gastroenterol. 2008 Feb 7;14(5):731-6 - PubMed
  16. J Gastroenterol Hepatol. 2009 Apr;24(4):672-80 - PubMed
  17. J Pak Med Assoc. 2014 Jul;64(7):820-2 - PubMed
  18. Ann Gastroenterol. 2015 Apr-Jun;28(2):158-159 - PubMed
  19. Rev Neurosci. 2015;26(6):699-719 - PubMed
  20. Evid Based Complement Alternat Med. 2007 Mar;4(1):43-50 - PubMed
  21. World J Gastroenterol. 2003 Dec;9(12):2791-5 - PubMed
  22. Phytomedicine. 2010 May;17(6):397-403 - PubMed
  23. World J Gastroenterol. 2012 Feb 21;18(7):589-600 - PubMed
  24. Gastroenterology. 2007 Mar;132(3):913-20 - PubMed
  25. Acta Pharm. 2007 Mar;57(1):123-9 - PubMed
  26. Front Psychiatry. 2015 Feb 16;6:15 - PubMed
  27. J Neurogastroenterol Motil. 2011 Jul;17(3):213-34 - PubMed
  28. Adv Pharmacol Sci. 2013;2013:101759 - PubMed
  29. Arch Dermatol Res. 2014 Sep;306(7):601-17 - PubMed
  30. Arch Med Res. 2005 Jul-Aug;36(4):376-81 - PubMed
  31. Clin Exp Pharmacol Physiol. 2014 Feb;41(2):118-26 - PubMed
  32. Neurogastroenterol Motil. 2006 Feb;18(2):115-22 - PubMed
  33. Acta Pol Pharm. 2003 Nov-Dec;60(6):467-70 - PubMed
  34. Indian J Pharmacol. 2012 Mar;44(2):189-92 - PubMed
  35. Asian Pac J Trop Med. 2014 Sep;7S1:S527-33 - PubMed
  36. J Neurogastroenterol Motil. 2016 Apr 30;22(2):310-20 - PubMed
  37. Neurochem Res. 2009 May;34(5):973-83 - PubMed
  38. J Gastroenterol. 2011 Apr;46(4):421-31 - PubMed
  39. World J Gastroenterol. 2015 Jun 28;21(24):7362-6 - PubMed
  40. Gastroenterology. 2000 Nov;119(5):1276-85 - PubMed
  41. Pharmacology. 2015;96(1-2):76-85 - PubMed
  42. J Ethnopharmacol. 2016 Jul 21;188:204-28 - PubMed
  43. Anal Biochem. 1976 May 7;72:248-54 - PubMed
  44. CNS Drugs. 2013 Apr;27(4):301-19 - PubMed
  45. Scand J Gastroenterol. 2014 Dec;49(12):1493-8 - PubMed
  46. J Neurogastroenterol Motil. 2016 Oct 30;22(4):558-574 - PubMed
  47. Iran Red Crescent Med J. 2013 Sep;15(9):813-6 - PubMed

Publication Types